• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Intermittent Claudication - Pipeline Review, H2 2012 Product Image

Intermittent Claudication - Pipeline Review, H2 2012

  • Published: November 2012
  • 65 pages
  • Global Markets Direct

Intermittent Claudication – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Intermittent Claudication - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Intermittent Claudication, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Intermittent Claudication. Intermittent Claudication - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Intermittent Claudication.
- A review of the Intermittent Claudication products under READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Intermittent Claudication Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Intermittent Claudication 8
Intermittent Claudication Therapeutics under Development by Companies 10
Intermittent Claudication Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Discovery and Pre-Clinical Stage Products 15
Comparative Analysis 15
Intermittent Claudication Therapeutics – Products under Development by Companies 16
Intermittent Claudication Therapeutics – Products under Investigation by Universities/Institutes 17
Companies Involved in Intermittent Claudication Therapeutics Development 18
Nissan Chemical Industries, Ltd. 18
Sangamo BioSciences, Inc. 19
Kowa Company, Ltd. 20
Cytokinetics, Inc 21
Pluristem Therapeutics Inc. 22
LTT Bio-Pharma Co., Ltd. 23
Diffusion Pharmaceuticals LLC 24
Phage Biotechnology Corporation 25
Intermittent Claudication – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
LT-0101 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ecraprost - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
tirasemtiv - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
PLX-PAD - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
K-134 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
FGF-1 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Trans Sodium Crocetinate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
EW-A-401 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
parogrelil - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CK-2066260 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CK-2127107 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Autologous CD34-Positive Cells - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Intermittent Claudication Therapeutics – Drug Profile Updates 48
Intermittent Claudication Therapeutics – Discontinued Products 57
Intermittent Claudication Therapeutics - Dormant Products 58
Intermittent Claudication – Product Development Milestones 59
Featured News & Press Releases 59
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells 59
Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research 59
Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study 60
Apr 17, 2012: Pluristem Receives FDA Clearance For Phase II Clinical Trial In Intermittent Claudication 60
Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134 61
Dec 02, 2011: Kowa Releases Japan Phase IIb Clinical Trials Data Of Anti-Platelet Agent, K-134 61
Nov 10, 2011: Kowa Announces Efficacy And Safety Of K-134 For Treatment Of Intermittent Claudication In AHA 2011 61
Jan 18, 2011: Pluristem To Proceed To Phase II/III Clinical Trial In Critical Limb Ischemia Under Joint FDA-EMA Protocol, And Phase II Clinical Trial In Intermittent Claudication 62
Aug 26, 2009: Taisho Pharmaceutical Co., Ltd. And Nissan Chemical Industries, Ltd. Announces The Discontinuation Of Development Of NT-702 For A Part Of Indications 62
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables
Number of Products Under Development for Intermittent Claudication, H2 2012 8
Products under Development for Intermittent Claudication – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
Nissan Chemical Industries, Ltd., H2 2012 18
Sangamo BioSciences, Inc., H2 2012 19
Kowa Company, Ltd., H2 2012 20
Cytokinetics, Inc, H2 2012 21
Pluristem Therapeutics Inc., H2 2012 22
LTT Bio-Pharma Co., Ltd., H2 2012 23
Diffusion Pharmaceuticals LLC, H2 2012 24
Phage Biotechnology Corporation, H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Stage and Molecule Type, H2 2012 30
Intermittent Claudication Therapeutics – Drug Profile Updates 48
Intermittent Claudication Therapeutics – Discontinued Products 57
Intermittent Claudication Therapeutics – Dormant Products 58

List of Figures
Number of Products under Development for Intermittent Claudication, H2 2012 8
Products under Development for Intermittent Claudication – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Discovery and Pre-Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 26
Assessment by Route of Administration, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 28
Assessment by Molecule Type, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 30

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos